THE UNIVERSITY of ADELAIDE
Department of Psychological Medicine
Women's and Children's Hospital
North Adelaide, 5006
Australia

October 14 2014

James Shannon
Chief Medical Officer
GlaxoSmithKline
980 Great West Road
Brentford, Middlesex TW8 9GS
United Kingdom

Dear Dr Shannon

Thank you for your letter dated 24 September 2014, and the time spent in formulating a response to our paper.

We have considered your comments. Unfortunately there are few points of agreement. We have two questions:

1. With regard to analyses of variables that '*were developed prior to opening the blind*', do you agree that if these analyses were to be conducted, it should be in accordance with the statistical methodology as set out at 9.3.3 of the study 329 protocol?

2. Can you provide evidence that the HAM-D depression item was designated as an outcome variable prior to the breaking of the blind?

Yours sincerely

Jon Jureidini
On behalf of the Study 329 RIAT team